In light of the heavy amount of announcements this morning, a summary of each company (IAM, MPAC, GTYH and AHPA) has been provided below.
I-AM Capital (IAM)
I-AM Capital filed a preliminary proxy to hold their shareholder vote on November 9th, this Friday. Additionally, I-AM has entered into a Forward Purchase Agreement (but in reverse) with Polar Asset Management, in which Polar has agreed to sell 490,000 shares of I-AM Capital common stock to I-AM Capital 30 days after the closing of the Business Combination for $11.23 per share. PLUS, Polar will also get 150,000 restricted shares of I-AM Capital common stock.
Basically, Polar will hang on to I-AM’s shares so that I-AM can secure the vote and then will sell back to I-AM 30 days post-business combination at $11.23.
Furthermore, the “Special Dividend” of 600,000 shares that were to go to shareholders still holding I-AM’s shares post-vote, has been cancelled. No need for it now that I-AM is working with Polar.>/p>
A summary of the changes to the proxy are provided below:
- The board of directors of I-AM Capital has set November 9, 2018 as the revised date of the special meeting;
- the Subscription Agreement has been amended to allow for the issuance of the Upfront I-AM Shares to the Transferring Smaaash Founders;
- the board of directors of I-AM Capital has decided to cancel the Special Dividend;
- I-AM Capital has entered into a forward stock purchase agreement for approximately $5,500,000; and
- the Smaaash Founders may, but are not obligated to, engage in private purchases and open market purchases of outstanding shares of I-AM Capital common stock.
Matlin & Partners (MPAC)
This morning, Matlin & Partners announced the results of their vote to complete their business combination with U.S. Well Services. It passed, but again, we had another SPAC with a lot of redemptions. Per their 8-K, 28,856,991 shares opted to redeem out of the 31,259,111 shares that were subject to possible redemption (as of their latest 10-Q). MPAC did not release the price at which those shares were redeemed, but if there are only 2,402,120 shares that didn’t and we use a conservative estimate of $10.17 pro rata per share, that means there is roughly only $25 million left in trust out of the $329.5 million as of September 30, 2018.
The amount left in trust is just an estimate since these figures are as of one month ago and as we’ve seen, a lot can happen in one month. The actual number of shares subject to redemption at vote could be a lot less than the stated 31,259,111. We’ll have to wait and see at their 10-Q.
GTY Technology Holdings (GTYH)
This morning, GTYH announced the results of their vote to extend their completion deadline to May 1, 2019. The vote passed, but per their 8-K, “34,011,538 shares out of a total of 55,200,000 shares of the Company’s Class A ordinary shares were redeemed. As a result, approximately $216.8 million still remains in the trust account.” Again, more redemptions than a SPAC wants to see, but GTYH still has over $200 million left in trust.
Avista Healthcare Public Acquisition Corp. (AHPA)
Avista filed a preliminary proxy this morning for their business combination with Organogenesis. Among other proposals that include the approval of the combination, there is the issuance of more than 20% of AHPAC’s issued and outstanding ordinary shares (or issued and outstanding common stock following the domestication) to the stockholders of Organogenesis and to participants in the equity financing in order to comply with Nasdaq’s listing rules.
InterPrivate II Acquisition Corp. (NYSE:IPVA) disclosed this morning that it has restructured its bonus share agreement in connection to its proposed merger with carsharing marketplace Getaround. The parties previously agreed to reserve and set aside the bonus shares, consisting of 9,333,333 shares, to be allocated to the non-redeeming public stockholders, the designees of EarlyBirdCapital and the...
Iris Acquisition Corp. (NASDAQ:IRAA) has entered into a definitive agreement to combine with biotech firm Liminatus at an enterprise value of $334 million. La Palma, California-based Liminatus is a clinical-stage drug developer working on a range of cancer treatments utilizing both preventative vaccines and CAR-T therapies. The combined company is expected to trade on the...
Lakeshore Acquisition Corp. I (NASDAQ:LAAA) announced this morning that it has entered into a non-redemption agreement and amended its purchaser support agreement with initial shareholders in connection to its proposed merger with medical device company ProSomnus. The SPAC entered into non-redemption agreements with certain institutional investors for an aggregate of 200,339 shares of the purchaser. These investors...
The companies and sponsors of six SPAC deals are set to see their lock-ups expire before the end of the year. This is a relatively small monthly total as the wave of deals from 2020 and 2021 are still hitting this milestone. The list nonetheless includes some major names starting with Forafric (NASDAQ:AFRI), which is...
Pacifico Acquisition Corp. (NASDAQ:PAFO) disclosed this afternoon that its shareholders have approved its business combination with sustainable shipping company Caravelle during a special meeting held earlier today. At today’s special meeting, 6,194,813 shares voted by proxy or in person, representing 82.65% of the total outstanding shares. The business combination was overwhelmingly approved as it received a...